Browsing Category
Pharma Industry News
4141 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Algorae Pharmaceuticals (ASX: 1AI) raises A$4m to fund dual commercial and AI drug discovery growth strategy
Algorae Pharmaceuticals (ASX: 1AI) raises A$3.99m to scale AlgoraeRx commercial portfolio and advance AlgoraeOS AI drug pipeline. Read the full strategic analysis.
April 5, 2026
Is Everus Construction Group building a stronger pharma and industrial moat through the SE&M acquisition?
Everus Construction Group is buying SE&M for $158 million to expand in the Southeast. Read what the deal means for growth, margins, and investor sentiment.
April 4, 2026
Why Context Therapeutics (NASDAQ: CNTX) jumped on CTIM-76 fast track status and what comes next
Context Therapeutics stock rose after CTIM-76 won FDA fast track status. Read what it means for CNTX, ovarian cancer strategy, and the June 2026 data catalyst.
April 4, 2026
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
April 4, 2026
Granules India (NSE: GRANULES) exits FDA audit with four observations as regulatory scrutiny intensifies
Granules India's Chantilly facility exits a routine US FDA cGMP audit with four procedural Form 483 observations and no data integrity findings. Read what it means for the GRANULES growth outlook.
April 4, 2026
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
April 4, 2026
Orchid Pharma company profile: business model, financials, and growth outlook (2026 Edition)
Orchid Pharma Limited company profile: cephalosporin API leader, FY2025 revenue Rs. 921.93 Cr, Jammu PLI expansion, novel antibiotic pipeline, and 2026-27 growth outlook.
April 4, 2026
Stablepharma company profile: Business model, pipeline, and growth outlook (2026 edition)
Stablepharma is a UK biotech developing fridge-free vaccines and injectables via its StablevaX platform. Explore its Phase 1 pipeline, AFT Pharmaceuticals partnership, and 2026-2027 growth outlook.
April 4, 2026
Could non-invasive vagus nerve stimulation emerge as an adjunctive pathway for chronic mild traumatic brain injury and PTSD management?
Could electroCore’s non-invasive vagus nerve stimulation expand into chronic mild traumatic brain injury and PTSD care? Read the strategic implications.
April 4, 2026
How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy
Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next.
April 4, 2026